💊 Osservatorio Regolatorio Pharma

Regulatory intelligence quotidiana e gratuita

Pubblicazioni dal 05/08/2026 06:25 a ora — 18 news

Gazzetta Ufficiale – Serie Generale (2)

AGENZIA ITALIANA DEL FARMACO - COMUNICATO
Modifica dell'autorizzazione all'immissione in commercio del medicinale per uso umano, a base di immunoglobulina umana anti-D, «Immunorho». (26A03806)
Apri →
AGENZIA ITALIANA DEL FARMACO - COMUNICATO
Modifica dell'autorizzazione all'immissione in commercio dei medicinali per uso umano, a base di vaccini antinfluenzali trivalente e tetravalente (virione split, inattivato), «Efluelda» e «Efluelda Tetra». (26A03807)
Apri →

EMA – What's new (15)

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Iqirvo, elafibranor, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Humira, adalimumab, Date of authorisation: 08/09/2003, Revision: 98, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 5, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Date of authorisation: 27/10/2020, Revision: 5, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Signifor, pasireotide, Date of authorisation: 24/04/2012, Revision: 16, Status: Authorised
Apri →
PSUSA/00000736/202509
Apri →
PSUSA/00000669/202512
Apri →
Human medicines European public assessment report (EPAR): Degarelix Accord, degarelix, Date of authorisation: 29/09/2023, Revision: 1, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Date of authorisation: 21/11/2016, Revision: 21, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Nexpovio, selinexor, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Kyprolis, carfilzomib, Date of authorisation: 19/11/2015, Revision: 22, Status: Authorised
Apri →
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 15, Status: Authorised
Apri →

EU Union Register of Medicinal Products (1)

Tavneos (Vifor Fresenius Medical Care Renal Pharma France)
Tavneos (Active substance: avacopan) - Referral - Commission Decision (2026) 5725 of Tue, 04 Aug 2026 - European Medicines Agency (EMA) procedure number: EMA/REF/0000325221
Apri →

Ti è utile? Inoltralo a un collega.

Per iscriversi: email vuota a osservatorio-pharma+subscribe@googlegroups.com (da qualsiasi indirizzo; poi rispondi all’email di conferma) — oppure groups.google.com/g/osservatorio-pharma (con account Google)

Servizio indipendente, gratuito.

← Torna all'archivio